Skip to Content
Merck
  • A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.

A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.

Nature communications (2015-03-18)
Ueli Nachbur, Che A Stafford, Aleksandra Bankovacki, Yifan Zhan, Lisa M Lindqvist, Berthe K Fiil, Yelena Khakham, Hyun-Ja Ko, Jarrod J Sandow, Hendrik Falk, Jessica K Holien, Diep Chau, Joanne Hildebrand, James E Vince, Phillip P Sharp, Andrew I Webb, Katherine A Jackman, Sabrina Mühlen, Catherine L Kennedy, Kym N Lowes, James M Murphy, Mads Gyrd-Hansen, Michael W Parker, Elizabeth L Hartland, Andrew M Lew, David C S Huang, Guillaume Lessene, John Silke
PMID25778803
ABSTRACT

Intracellular nucleotide binding and oligomerization domain (NOD) receptors recognize antigens including bacterial peptidoglycans and initiate immune responses by triggering the production of pro-inflammatory cytokines through activating NF-κB and MAP kinases. Receptor interacting protein kinase 2 (RIPK2) is critical for NOD-mediated NF-κB activation and cytokine production. Here we develop and characterize a selective RIPK2 kinase inhibitor, WEHI-345, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. Despite only delaying NF-κB activation on NOD stimulation, WEHI-345 prevents cytokine production in vitro and in vivo and ameliorates experimental autoimmune encephalomyelitis in mice. Our study highlights the importance of the kinase activity of RIPK2 for proper immune responses and demonstrates the therapeutic potential of inhibiting RIPK2 in NOD-driven inflammatory diseases.